「敏捷医疗」获数亿元B轮融资，加速腔镜手术机器人临床应用｜早起看早期

Core Viewpoint - Agile Medical has completed a multi-hundred million RMB Series B financing round, aimed at global commercialization, product development, and technology platform upgrades [3]. Group 1: Product Development and Clinical Application - The core product AGIBOT® laparoscopic surgical robot is expected to be approved for market launch by March 2025, with over 100 complex surgical applications already completed in top-tier hospitals [3]. - The AGIBOT® features an integrated suspension design and a dual-guidance system combining laser and camera visualization, reducing average docking time to under 3 minutes [3]. - The robot enhances operational flexibility and precision, providing over 96 liters of effective operational space for surgeons during complex laparoscopic procedures [4]. Group 2: Innovation and Data Utilization - Agile Medical emphasizes clinical needs in product development, integrating frontline feedback into the R&D process to address challenges in medical-engineering integration [3][4]. - The increasing clinical cases of the laparoscopic surgical robot allow the intelligent platform to collect more surgical data, which can be analyzed using artificial intelligence for further product optimization [4]. Group 3: Commercialization and Supply Chain - Cost control and supply chain management are critical for the laparoscopic surgical robot's competitiveness in both domestic and international markets [5]. - Agile Medical has adopted a fully self-researched core technology path and established a research and production base in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually [5]. - The company plans to enhance capabilities in force feedback and AI, aiming for smarter surgical robots, while also initiating overseas certification and engaging with potential clinical partners in international markets [5].